Find A Doctor Profile | VCU Health

Dr. Masey M. Ross

Claim this profile

Virginia Commonwealth University/Massey Cancer Center

Studies Breast Cancer
Studies Breast cancer
12 reported clinical trials
26 drugs studied

Area of expertise

1

Breast Cancer

Masey M. Ross has run 10 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
HER2 positive
ER positive
2

Breast Cancer

Masey M. Ross has run 9 trials for Breast cancer. Some of their research focus areas include:

HER2 negative
ER positive
PR positive

Affiliated Hospitals

Image of trial facility.

Virginia Commonwealth University/Massey Cancer Center

Image of trial facility.

VCU Massey Cancer Center At Stony Point

Clinical Trials Masey M. Ross is currently running

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

More about Masey M. Ross

Clinical Trial Related

2 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Masey M. Ross has experience with

  • Paclitaxel
  • Fulvestrant
  • Quality-of-Life Assessment
  • Durvalumab
  • Chemotherapy
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Masey M. Ross specialize in?

Is Masey M. Ross currently recruiting for clinical trials?

Are there any treatments that Masey M. Ross has studied deeply?

What is the best way to schedule an appointment with Masey M. Ross?

What is the office address of Masey M. Ross?

Is there any support for travel costs?